Risk factors for post-transplant lymphoproliferative disorder after pediatric liver transplantation in China

Li-min Liu
Shanghai Childrens Medical Center

Zhao-hui Deng (✉ dengzhaohui@scmc.com.cn)
Shanghai Childrens Medical Center Affiliated to Shanghai Jiaotong University School of Medicine

Kai-hua Yang
Shanghai Childrens Medical Center

Tao Zhou
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Guang-xiang Gu
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Research

Keywords: risk factors, post-transplant lymphoproliferative disorder, liver transplantation

DOI: https://doi.org/10.21203/rs.3.rs-128627/v1

License: 📩 This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Objectives: This study aimed to analyze the risk factors associated with post-transplant lymphoproliferative disorder (PTLD) after liver transplantation in children.

Methods: We retrospectively analyzed the clinical and laboratory data of patients treated and followed up at Shanghai Children's Medical Center between January 2012 and January 2019. Twenty-four patients with PTLD were enrolled in this study using a 1:2 pairing design. Each case was matched with two controls that had undergone liver transplantation within the same year but did not develop PTLD during the follow-up period. A total of 72 patients were included in this study.

Results: Univariate analysis demonstrated statistically significant differences in Epstein-Barr virus (EBV) infection, tacrolimus blood concentration, Platelet (PTL), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), and Cholesterol (CHOL). Multivariate logistics regression analysis revealed that EBV infection was an independent risk factor for PTLD.

Conclusions: EBV infection is an independent risk factor for PTLD. When uncontrolled proliferation of EBV occurs after organ transplantation, the dosage of immunosuppressive agents should be appropriately reduced.

Introduction

Currently, liver transplantation is the only effective way to treat end-stage liver diseases such as intrahepatic and extrahepatic cholestasis, metabolic diseases, acute liver failure, and liver tumors in children. Advanced surgical techniques and immunosuppressants have significantly improved the overall survival rate of pediatric patients undergoing liver transplantation. The 5-year survival rate of pediatric patients undergoing liver transplantation in developed countries is as high as 80%1. Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication that can occur following pediatric liver transplantation. PTLD has various clinical manifestations and is difficult to diagnose early. Most patients have a poor prognosis with a mortality rate of 30–60%. The incidence of PTLD after liver transplantation in children is 1–5%2,3,4, with a mostly poor prognosis5.

Epstein-Barr virus (EBV) is among the most frequently observed viral pathogens affecting pediatric patients undergoing liver transplant, and EBV infection is closely related to the incidence of PTLD6. Similarly, studies have identified tacrolimus as one of the risk factors for PTLD. Tacrolimus administration after transplantation is known to increase the incidence of malignant tumors and PTLD in patients7,8,9. Additionally, the patient’s age at transplantation (between 1–10 years old) and occurrence of acute rejection after transplantation are related to the occurrence of PTLD10,11.
The risk factors associated with PTLD after liver transplantation have not been studied in the Chinese pediatric population. Therefore, we conducted a single-center retrospective study to investigate the risk factors for PTLD after liver transplantation in China.

**Methods**

**Patients**

All patients were treated and followed up at Shanghai Children's Medical Center. The medical records of patients aged 1–2 years, who underwent liver transplantation between January 2012 and January 2019, were reviewed. All patients included in this study were diagnosed with PTLD between January 2012 and January 2019. Patients who died during the follow-up period were excluded from this analysis. Control patients were matched (1:2) according to the type of organ transplanted and period since transplantation (within one year). The control patients were recruited from a cohort of transplant recipients who did not have PTLD and underwent a transplant during the same period as the study subjects. Clinical characteristics and laboratory findings were extracted from the medical records of each patient and analyzed.

**Diagnosis**

EBV DNA >5,000 IU/mL in the peripheral blood was diagnosed as Epstein-Barr viremia. A workup for PTLD was initiated when indicated based on clinical symptoms, including unexplained weight loss, fever, gastrointestinal bleeding, anemia, thrombocytopenia, hypoalbuminemia, or lymphadenopathy/tonsillar hypertrophy in the absence of infection. Evaluation included cross-sectional imaging, positron emission tomography scans, and endoscopy and biopsy. Additionally, some cases of PTLD were incidentally diagnosed during endoscopic graft surveillance, allograft resection, and/or ostomy takedown. The sample obtained was examined by a pathologist and classified according to established criteria.

**Data extraction**

All data sources were extracted from the medical record management system of the hospital. Keywords, including “lymphocyte proliferative diseases after transplantation” and liver transplantation”, were used to search the database. The collected indicators included: the (1) basic information: gender, primary disease, age at transplantation, and weight, among others; (2) laboratory indicators: White blood cell (WBC), hemoglobin (HBG), Neutrophil (NE), PLT, ALT, AST, Total bilirubin (TBIL), Direct Bilirubin (DBIL), Albumin (ALB), Alkaline phosphatase (AKP), Gamma-glutamyl transpeptidase (γ-GGT), Creatinine (CREA), Blood urea nitrogen (BUN), blood glucose (GLU), (Prothrombin time (PT), International normalized ratio (INR), Triglyceride (TG), CHOL), and tacrolimus concentration; (3) transplantation-related indicators: transplantation method, graft weight, graft/weight ratio, intraoperative blood loss, and blood type; (4) viral infection: preoperative EBV
and cytomegalovirus (CMV) infections, time interval between surgery, and the first EBV/CMV infection; (5) donor information: blood type, preoperative EBV, and CMV infection, among others.

Treatment

Data were extracted from hospital medical records, and demographic, clinical, treatment, and laboratory data were obtained. All patients who underwent liver transplantation received an anti-immune rejection regimen of tacrolimus and steroids on the first postoperative day. The initial tacrolimus dose was 0.1–0.15 mg/kg/d, and the ideal blood concentrations were as follows: one month after transplantation, the serum tacrolimus concentration should be maintained within 8–12 ng/mL; 2–6 months postoperatively, the serum tacrolimus concentration should be maintained between 7 and 10 ng/mL before being reduced to 5–8 ng/mL at 7–12 months and maintained at 5 ng/mL, as appropriate, 12 months after transplantation. During this period, the drug dosage can be adjusted according to the tacrolimus blood concentration and EBV copy number. The total duration of hormone treatment was short. The first glucocorticoid dose was intravenously administered during the non-hepatic stages of surgery. The intravenous glucocorticoid dose was reduced to 4 mg/kg/d within one week postoperatively, and oral glucocorticoids (e.g. prednisone, initial dose of 0.25–1 mg/kg/d) were administered one week postoperatively. Patients with no abnormalities should stop glucocorticoid therapy at the earliest possible opportunity within 3–6 months postoperatively.

Follow-up

The outpatient follow-up plan mainly included laboratory tests and imaging examinations, which were designed to monitor graft morphology and blood flow. If the patient suffered from unexplained weight loss, fever, gastrointestinal bleeding, anemia, thrombocytopenia, hypoproteinemia, or lymphadenopathy during follow-up, they were informed of the possibility of PTLD. Examinations, such as virological monitoring (EBV and CMV), abdominal and lymph node B-ultrasound, gastrointestinal endoscopy, and positron emission computed tomography, were selected according to the clinical manifestations. Imaging examination revealed that patients with obvious abnormal lesions could undergo surgery or gastrointestinal endoscopy to obtain biopsies, which can subsequently facilitate efficient and targeted treatment options based on different pathological manifestations.

Statistical analysis

Potential risk factors for PTLD were determined by comparing different variables between patients with PTLD and control subjects using SPSS Software. Primary analyses were conducted using a Student’s t-test and chi-squared test. To eliminate confounding factors affecting the results, multivariate logistic regression analysis was conducted to further analyze the results. A P-value <0.05 was considered statistically significant.
Results

Baseline characteristics

After screening, according to the inclusion and exclusion criteria, a total of 24 patients in the PTLD group were included. Furthermore, a total of 48 control patients were enrolled.

The descriptive characteristics of the study subjects are shown in Table 1. Male and female patients comprised 33.3% and 66.7% and 37.5% and 62.5% of the PTLD and control groups, respectively. The average age at transplantation for patients with PTLD was 9.96 months (minimum age, 5 months; maximum age, 24 months). Conversely, the average age at transplantation in the control group was 8.60 months (minimum age, 5 months; maximum age, 24 months). No significant difference was observed in the distribution of transplantation age and sex between the two groups. Among the included cases, the primary disease affecting both groups was biliary atresia.

Laboratory indicators and liver transplantation characteristics

Analysis of preoperative laboratory indicators (Table 2), including blood tests (WBC, HBG, NE, PLT), liver and kidney function tests (ALT, AST, TBIL, DBIL, ALB, AKP, γ-GGT, BUN, CREA), GLU, coagulation function (PT, INR), and blood lipids (TG, CHOL) between the PTLD and control groups revealed statistically significant differences in postoperative platelets, ALT, AST, CHOL, and serum tacrolimus concentration (all P<0.05). Patients received tacrolimus after liver transplantation, and their serum tacrolimus concentrations were continuously monitored. The average postoperative serum tacrolimus concentrations of patients in the PTLD and control groups were 8.28±1.61 ng/mL and 7.32±1.63 ng/mL, respectively (P<0.05; Table 2).

Graft weight, graft body weight ratio, transplant type, intraoperative blood loss, and blood type were not related to the occurrence of PTLD (Table 2).

Viral infection

The incidences of EBV and CMV replication after post-transplantation were analyzed in patients and donors. EBV and CMV infection rates were 95.8% and 20.8% and 48.9% and 22.9% in the PTLD and control groups, respectively. A significant difference in the EBV infection rates was observed between the two groups. Statistical analysis demonstrated that EBV infection was an important risk factor for PTLD (P<0.001). No association was observed between CMV infection and PTLD in this study. The EBV and CMV infection statuses of donors before transplantation were classified as follows: donor-positive/recipient-negative, donor-positive/recipient-positive, donor-negative/recipient-positive, and donor-negative/recipient-negative. The viral infection status of donors and recipients before surgery were not statistically associated (P>0.05; Table 3).

Risk factors for PTLD after liver transplantation
Multivariate analysis identified EBV infection as an independent risk factor for PTLD (P<0.05). Tacrolimus concentration, ALT, AST, PLT, and CHOL had varying degrees of difference in the incidence of PTLD; however, no statistical differences were identified (Table 4).

Discussion

Several studies have confirmed that EBV infection is directly related to the incidence of PTLD\textsuperscript{12,13}, which was confirmed by the findings of this study. In this study, the EBV infection rate of patients with PTLD was 95.8%, suggesting that EBV infection is an important risk factor for PTLD. In the PTLD group, the time of peak EBV replication was closely related to the time of PTLD onset, indicating that PTLD is likely to occur when EBV infection undergoes rapid replication and is at or near its peak. Therefore, monitoring changes in the EBV copy number in transplant patients will allow clinicians to monitor PTLD and appropriately adjust the level of immunosuppressants administered. Immunotherapy with monoclonal antibodies, particularly anti-CD20 antibody (rituximab), is the first-line treatment for patients who do not respond to a reduction or discontinuation of immunosuppressants. In several studies, rituximab administered as treatment yielded a 40–68% response rate. In a preemptive setting, the anti-CD20 antibody can prevent EBV-associated PTLD in approximately 90% of cases. Furthermore, changes in the EBV copy number may prompt the use of rituximab therapy\textsuperscript{14}. A recent study observed that the initial application of rituximab should be performed in patients whose EBV DNA load is > 40,000 U/mL after transplantation if they similarly exhibited at least one symptom of PTLD or demonstrated evidence of PTLD upon imaging\textsuperscript{15}.

CMV infection is common after liver transplantation in children and is associated with the following symptoms: fever of unknown origin (38.3 °C), fatigue or systemic myalgia, and leukopenia or thrombocytopenia. The relationship between CMV infection and PTLD remains unclear. Some studies believe that CMV infection is a risk factor for PTLD, although the underlying mechanism is currently unknown. Most studies consider that CMV infections are not related to the occurrence of PTLD. Kim et al.\textsuperscript{16} analyzed 119 liver transplant patients. Among them, 66 (55.5%) patients had CMV infection, and 15 patients eventually developed PTLD. Among them, 10 patients with PTLD had a CMV infection, whereas five had no CMV infection. Statistical analysis showed that the occurrence of PTLD was not related to CMV infection (P = 0.258). In this study, the CMV infection rate was 22.2%, and the final incidence of PTLD in CMV-infected patients was 31.2%. No statistically significant relationship was observed between CMV infection and PTLD.

Studies have shown that donor EBV\textsuperscript{+}/recipient EBV\textsuperscript{−} is an important risk factor for PTLD as a high EBV infection rate can cause PTLD in younger patients. A previous study observed that in donor EBV\textsuperscript{+}/recipient EBV\textsuperscript{−} patients, 67% of patients developed postoperative EBV infection. A higher postoperative EBV infection rate increases the risk of PTLD in patients. EBV-negative patients receiving EBV-positive organs are at a high risk of developing PTLD\textsuperscript{17}. This study assessed the viral infection status of donors. Seven of the study patients received cadaveric liver transplants; thus, in these cases, the
infection status of the donor could not be obtained. Only 65 patients who underwent liver transplants were analyzed, and the viral infection rate of donors was not high, and no statistical significance was identified, most likely due to the small sample size.

Some studies have suggested that high serum tacrolimus concentrations are a risk factor for PTLD onset\(^\text{18}\). Fukushima et al.\(^\text{19}\) analyzed the changes in tacrolimus concentrations when the EBV load continued to increase and observed that the PTLD group had significantly higher tacrolimus concentrations compared to the control group. Other research has focused on the correlation between tacrolimus and EBV infection. By monitoring serum tacrolimus concentrations within two weeks of liver transplantation, Lu et al.\(^\text{20}\) found that the EBV infection rate increased within 2–4 weeks postoperatively in patients with a high serum tacrolimus concentration. Bakker et al.\(^\text{21}\) observed that when immunosuppressant dosages were reduced in patients suffering from uncontrolled, postoperative EBV infections, the EBV load significantly reduced.

This study evaluated the relationship between serum tacrolimus concentrations and PTLD. Univariate analysis revealed a significant difference in the serum tacrolimus concentrations (\(P = 0.021\)). At higher levels of immunosuppression, EBV is prone to uncontrolled proliferation because tacrolimus acts upon both B and T lymphocytes while suppressing humoral and cell-mediated immunity. This subsequently leaves patients susceptible to EBV infections after surgery and makes it difficult to control EBV proliferation after infection\(^\text{22,23}\). However, multivariate analysis demonstrated that serum tacrolimus concentrations were not a risk factor for PTLD, although the patients in the PTLD group had higher serum tacrolimus concentrations than those in the control group. In view of the fact that EBV infection is a risk factor for PTLD, it is suggested that when uncontrolled proliferation of EBV occurs after organ transplantation, the dosage of immunosuppressive agents should be appropriately reduced to prevent PTLD.

In this study, no associations were observed between baseline characteristics, laboratory indicators, and transplant-related indicators and the occurrence of PTLD. Currently, the relationship between the age at transplantation and incidence of PTLD is controversial. A study observed that younger patients undergoing organ transplantation were at a greater risk of PTLD, especially children 1–10 years old\(^\text{24}\). Another study concluded that the risk of postoperative PTLD was reduced by 15% with a yearly increase in age\(^\text{25}\) and found that younger patients (at the time of transplantation) is a risk factor for postoperative EBV and CMV infections\(^\text{26}\). In this study, no association was observed between the age at transplantation and occurrence of PTLD, possibly because the primary disease of patients was mostly biliary atresia, and the transplantation age of patients was generally within two years. Young patients are more likely to be susceptible to PTLD because they have a higher viral infection rate than adults at the time of transplantation.

**Conclusion**
PTLD is a life-threatening complication that can occur in children following liver transplantation. Baseline characteristics, laboratory indicators, and transplant-related indicators are not related to the occurrence of PTLD. The results of this study suggest that EBV infection is an independent risk factor for PTLD; therefore, it is necessary to be aware of the risk of PTLD occurrence when EBV is actively replicating or the viral load is high. In addition, tacrolimus is not a direct factor leading to the occurrence of PTLD; however, the degree of immunosuppression should be reduced in children with continuously replicating EBV and a high serum concentration of tacrolimus.

**Abbreviations**

| Abbreviations | Full-term                                      |
|---------------|------------------------------------------------|
| ALB           | Albumin                                        |
| ALKP          | Alkaline phosphatase                           |
| ALT           | Aspartate aminotransferase                     |
| AST           | Aspartate aminotransferase                     |
| CHOL          | Cholesterol                                    |
| CMV           | Cytomegalovirus                                |
| CREA          | Creatinine                                     |
| DBIL          | Direct Bilirubin                               |
| EBV           | Epstein-Barr virus                             |
| HGB           | hemoglobin                                     |
| INR           | International normalized ratio                 |
| γ-GGT         | Gamma-glutamyl transpeptidase                  |
| NE            | Neutrophil                                     |
| TBIL          | Total bilirubin                                |
| PLT           | Platelet                                       |
| PT            | Prothrombin time                               |
| PTLD          | Post-transplant lymphoproliferative disorder   |
| TG            | Triglyceride                                   |
| WBC           | White blood cell                               |

**Declarations**
Ethics approval and consent to participate: All analyses were based on previous blood test indicators, thus no ethical approval and patient consent are required.

Consent for publication: Not applicable.

Availability of data and materials: All data generated or analysed during this study are included in this published article.

Competing interests: The authors declare no conflicts of interest associated with this manuscript.

Funding: The authors declare no financial assistance received in support of the study.

Authors' contributions: Zhao-hui Deng, MD contributed to the conception and design of the study. The preparation of the material and collection and analysis of the data were performed by Li-min Liu, MM. Further, the first draft of the manuscript and statistical analysis were written by Li-min Liu, MM and Kaihua Yang, MM. Tao Zhou, MM added comments to the first and subsequent versions of the manuscript. Li-min Liu, MM wrote the final revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements: Not applicable.

References

1. Kasahara M, Umeshita K, Inomata Y, et al. Long-term outcomes of pediatric living donor liver transplantation in Japan analysis of more than 2,200 cases listed in the registry of the Japanese Liver Transplantation Society. Am J Transplant 2013;13:1830-9.

2. Lauro A, Arpinati M, Pinna AD. Managing the challenge of PTLD in liver and bowel transplant recipients. Br J Haematol 2014;169:157-72.

3. Kumarasinghe G, Lavee O, Parker A, et al. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. J Heart Lung Transplant 2015;34:1406-14.

4. Martin M, Tilmann S, Uta B, et al. Posttransplant lymphoproliferative disease after pediatric solid organ transplantation. Clin Dev Immunol 2013;(2013):1-14.

5. Jeong HJ, Ahn YH, Park E, et al. Posttransplantation lymphoproliferative disorder after pediatric solid organ transplantation: Experiences of 20 years in a single center[J]. Korean J Pediatr 2017;60:86-93.

6. Ruf S, Behnke-Hall K, Gruhn B, et al. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation. J Clin Virol 2012;53:186-94.

7. Schubert S, Renner C, Hammer M, et al. Relationship of immunosuppression to Epstein–Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant 2008;27:100-5.
8. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients—BCSH and BTS guidelines. Br J Haematol 2010;149:675-92.
9. Jagadeesh D, Woda BA, Draper J, Evens AM. Posttransplant lymphoproliferative disorders: Risk, classification, and therapeutic recommendations. Curr Treat Options in Oncol 2012;13:122-36.
10. Chinnock R, Webber SA, Dipchand AI, et al. A 16-Year multi-institutional study of the role of age and EBV Status on PTLD incidence among pediatric heart transplant recipients. American J Transplant 2012;12:3061-8.
11. Dolcetti R. B lymphocytes and Epstein–Barr virus: The lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 2008;7:96-101.
12. Young LS, Rickinson AB. Epstein–Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-68.
13. Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: The significance and application for each EBV-associated disease. Rev Med Virol 2008;18:305-19.
14. Kalra A, Roessner C, Jupp J, et al. Epstein-bar virus DNA-emia monitoring for the management of post-transplant lymphoproliferative disorder. Cytotherapy 2018;20:706-14.
15. Kim JM, Lee SK, Kim SJ, et al. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia. Transplant Proc 2010;42:895-9.
16. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001;3:70-8.
17. Jagadeesh D, Woda BA, Draper J, Evens AM. Posttransplant lymphoproliferative disorders: Risk, classification, and therapeutic recommendations. Curr Treat Options in Oncol 2012;13:122-36.
18. Fukushima D, Sato K, Kawagishi N, et al. Epstein-Barr virus–associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. Transplantation 2015;99:114-9.
19. Lu BR, Park KT, Hurwitz M, et al. Impact of immunosuppression on the development of Epstein-Barr virus (EBV) viremia after pediatric liver transplantation. Transplant Proc 2013;45:301-4.
20. Bakker NA, Verschuuren EAM, Erasmus ME, et al. Epstein-Barr virus-DNA load monitoring late after lung transplantation: A surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 2007;83:433-8.
21. Cosmas D, Wimmer, Martin K, et al. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: A single-center experience with 609 patients. Transpl Int 2013;26:999-1006.
22. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005;56:155-67.
23. Chinnock R, Webber SA, Dipchand AI, et al. A 16-Year multi-institutional study of the role of age and EBV Status on PTLD incidence among pediatric heart transplant recipients. Am J Transplant 2012;12:3061-8.
24. Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003;75:987-93.

25. Shepherd RW, Turmelle Y, Nadler M, et al. Risk factors for rejection and infection in pediatric liver transplantation. Am J Transplant 2008;8:396-403.

Tables

TABLE 1. Descriptive characteristics of the PTLD and control groups

|                          | PTLD cases (n=24) | Control (n=48) | $\chi^2$ / $t$ | P-value |
|--------------------------|-------------------|----------------|---------------|---------|
| Sex                      |                   |                |               |         |
| Male                     | 8 (33.3%)         | 18 (37.5%)     | 0.120         | 0.799   |
| Female                   | 16 (66.7%)        | 30 (62.5%)     |               |         |
| Disease                  |                   |                | 1.565         | 0.476   |
| Biliary atresia          | 24 (100%)         | 45 (93.7%)     |               |         |
| Alaki syndrome           | 0                 | 1 (2.1%)       |               |         |
| Hypercholesterolemia     | 0                 | 1 (2.1%)       |               |         |
| Methylmalonic acidemia   | 0                 | 1 (2.1%)       |               |         |
| Age at transplantation (months) (medians, ranges) | 9.96 (5-24) | 8.60 (5-24) | 1.230 | 0.223 |
| Weight at transplantation (kg) (medians, ranges) | 7.48 (4.5-11) | 7.21 (3.2-20) | 1.130 | 0.648 |

PTLD; post-transplant lymphoproliferative disorder

TABLE 2 Analysis of laboratory indicators and liver transplantation characteristics

Page 11/14
|                                | PTLD cases (n=24) | Control (n=48) | $\chi^2/t$ | P-value |
|--------------------------------|-------------------|----------------|-----------|--------|
| WBC ($\times 10^9$)           | 11.09±4.63        | 11.40±7.62     | -0.180    | 0.858  |
| HBG (g/L)                     | 93.69±25.47       | 98.19±14.49    | -0.957    | 0.342  |
| NE ($\times 10^9$)            | 8.16±16.26        | 6.60±9.01      | 0.525     | 0.601  |
| PLT ($\times 10^9$)           | 168.46±77.29      | 237.44±115.89  | -2.633    | 0.010  |
| ALB (g/L)                     | 38.04±19.50       | 34.68±4.82     | 1.134     | 0.260  |
| ALT (U/L)                     | 330.13±590.21     | 130.98±97.47   | 2.292     | 0.025  |
| AST (U/L)                     | 453.03±519.48     | 213.31±128.69  | 3.036     | 0.003  |
| ALKP (U/L)                    | 614.66±404.51     | 503.53±241.27  | 1.459     | 0.149  |
| γ-GGT (U/L)                   | 365.40±297.63     | 381.56±419.13  | -1.169    | 0.851  |
| TBIL ($\mu$mol/L)             | 226.63±135.87     | 250.76±154.15  | -0.650    | 0.518  |
| DBIL ($\mu$mol/L)             | 165.39±92.65      | 171.33±110.49  | -0.226    | 0.822  |
| CREA ($\mu$mol/L)             | 12.35±4.66        | 15.41±7.22     | -1.886    | 0.063  |
| BUN (mmol/L)                  | 11.32±37.78       | 2.81±1.29      | 1.571     | 0.121  |
| INR                            | 2.67±4.02         | 1.56±0.80      | 1.854     | 0.068  |
| PT(s)                          | 16.32±4.77        | 17.02±8.28     | -0.387    | 0.700  |
| TG (mmol/L)                    | 1.53±1.09         | 4.16±16.54     | -0.774    | 0.442  |
| CHOL (mmol/L)                  | 3.53±1.94         | 6.31±1.94      | -3.022    | 0.004  |
| Tacrolimus concentration (ng/mL) | 8.28±1.61        | 7.32±1.63      | 2.370     | 0.021  |
| Graft weight (g)               | 256.29±555.03     | 241.13±90.45   | 0.864     | 0.391  |
| Graft/weight ratio             | 3.39±0.89%        | 2.96±0.87%     | 1.976     | 0.643  |
| Type of transplant             |                   |                | 0.430     | 0.659  |
| living donor                   | 22 (91.7%)        | 43 (89.6%)     |           |        |
| cadaveric donors               | 2 (8.3%)          | 5 (10.4%)      |           |        |
| Intraoperative bleeding (mL)   | 204.35±152.19     | 283.33±162.86  | 1.952     | 0.550  |
| blood type                     |                   |                | 0.138     | 0.786  |
| matched                        | 18 (75%)          | 34 (70.8%)     |           |        |
| mismatched                     | 6 (25%)           | 14 (29.2%)     |           |        |
PTLD; post-transplant lymphoproliferative disorder

TABLE 3 Viral infection in PTLD cases and controls

|                          | PTLD cases (n=24) | Control (n=48) | $X^2/t$ | P-values |
|--------------------------|-------------------|----------------|---------|----------|
| **EBV infection**        |                   |                |         |          |
| Yes                      | 23 (95.8%)        | 23 (48.9%)     | 19.149  | <0.001   |
| No                       | 1 (4.2%)          | 25 (52.1%)     |         |          |
| **D-R EBV serostatus pretransplantation** |                 |                |         |          |
| D-R-                     | 21 (95.5%)        | 37 (86.0%)     | 1.819   | 0.403    |
| D+R-                     | 1 (4.5%)          | 3 (7.0%)       |         |          |
| D-R+                     | 0                 | 3 (7.0%)       |         |          |
| D+R+                     | 0                 | 0              |         |          |
| **CMV infection**        |                   |                |         |          |
| Yes                      | 5 (20.8%)         | 11 (22.9%)     | 0.040   | 1.000    |
| No                       | 19 (79.2%)        | 37 (77.1%)     |         |          |
| **D-R CMV serostatus pretransplantation** |                 |                |         |          |
| D-R-                     | 19 (86.4%)        | 39 (90.6%)     | 4.143   | 0.126    |
| D+R-                     | 2 (9.1%)          | 2 (4.7%)       |         |          |
| D-R+                     | 1 (4.5%)          | 2 (4.7%)       |         |          |
| D+R+                     | 0                 | 0              |         |          |

EBV; Epstein-Barr virus; CMV; cytomegalovirus; PTLD; pediatric liver transplantation;

D-R EBV serostatus pretransplantation; Seven of the study patients received cadaveric liver transplants, Only 65 patients who underwent liver transplants were analyzed.

TABLE 4. Multivariate analysis of factor for PTLD after liver transplantation
| Variable                        | B    | SE   | Wals | OR (95% CI)                  | P    |
|--------------------------------|------|------|------|------------------------------|------|
| Tacrolimus concentration (ng/mL) | 0.405 | 2.223 | 3.292 |                              | 0.070 |
| EBV infection                  | 3.308 | 1.125 | 8.647 | 27.329 (3.013-247.846)      | 0.003 |
| PLT                            | -0.009 | 0.005 | 3.201 | 0.991 (0.981-1.001)         | 0.074 |
| ALT                            | -0.015 | 0.008 | 3.656 | 0.985 (0.969-1.000)         | 0.056 |
| AST                            | 0.003  | 0.008 | 0.177 | 1.003 (0.998-1.019)         | 0.674 |
| CHOL                           | -0.241 | 0.245 | 0.972 | 0.786 (0.486-1.269)         | 0.786 |